Baxalta posts strong 4Q sales, earnings

Business Wire

BANNOCKBURN - Baxalta Inc. reported strong fourth quarter 2015 financial results, with global sales rising 5 percent.

Sales for the quarter were $1.8 billion, up 5 percent from the prior-year period. Excluding the impact of foreign currency, sales advanced 12 percent, the Baxter spinoff company announced. Fourth quarter net income was $387 million, or 57 cents per diluted share, which compares favorably to the company's previously-issued guidance of 55 to 57 cents per diluted share.

Global revenues increased 3 percent for the period. Excluding the impact of foreign currency, sales advanced 10 percent, exceeding the company's previously-issued guidance of growth in the 3 to 5 percent range. Within the United States, sales of $944 million rose 13 percent; international sales of $819 million declined 7 percent. Excluding foreign currency, international sales increased 8 percent.

For the full-year 2015, Baxalta reported worldwide revenues of $6.1 billion, a 3 percent increase over the prior-year period. Excluding the impact of foreign currency, sales advanced 11 percent.

"We are pleased to report another quarter of strong financial performance reflecting continued positive momentum across our entire portfolio," said Baxalta President and CEO Ludwig Hantson. "In 2015, Baxalta achieved its strategic objectives, exceeded our financial guidance with disciplined execution and established a solid foundation for the future. We will continue to build on this success with our commitment to patient-centric innovation and new product launches to drive enhanced growth and value for patients, customers and other key stakeholders."